Drug Profile
INGN 212
Latest Information Update: 04 Mar 2008
Price :
$50
*
At a glance
- Originator Introgen Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Colorectal cancer in Europe (unspecified route)
- 19 Jun 2001 INGN 212 is in active development
- 10 Dec 1998 New profile